Abstract
PET imaging agents such as Pittsburgh compound B (PiB) allow detection of fibrillar β-amyloid (Aβ) in vivo. In addition to quantification of Aβ deposition in mild cognitive impairment and Alzheimers disease, PiB has also increased our understanding of Aβ deposition in older adults without cognitive impairment. In vivo Aβ deposition has been studied in relation to genotype, structural and functional brain changes, as well as alterations in biomarker levels. To date, several studies have reported changes in Aβ burden over time. This, together with investigation of the relationship between Aβ deposition and cognition, sets the stage for elucidation of the temporal sequence of the neurobiological events leading to cognitive decline. Furthermore, correlation of Aβ levels detected by PiB PET and those obtained from biopsy or postmortem specimens will allow more rigorous quantitative interpretation of PiB PET data in relation to neuropathological evaluation. Since the first human study in 2004, in vivo amyloid imaging has led to advances in our understanding of the role of Aβ deposition in human aging and cognitive decline, as well as provided new tools for patient selection and therapeutic monitoring in clinical trials.
Keywords: PiB, amyloid, aging, MCI, AD, cognition, MRI, FDG, pathology, human, brain, APOE E4 allele
Current Alzheimer Research
Title: In Vivo Human Amyloid Imaging
Volume: 8 Issue: 4
Author(s): J. Sojkova and S. M. Resnick
Affiliation:
Keywords: PiB, amyloid, aging, MCI, AD, cognition, MRI, FDG, pathology, human, brain, APOE E4 allele
Abstract: PET imaging agents such as Pittsburgh compound B (PiB) allow detection of fibrillar β-amyloid (Aβ) in vivo. In addition to quantification of Aβ deposition in mild cognitive impairment and Alzheimers disease, PiB has also increased our understanding of Aβ deposition in older adults without cognitive impairment. In vivo Aβ deposition has been studied in relation to genotype, structural and functional brain changes, as well as alterations in biomarker levels. To date, several studies have reported changes in Aβ burden over time. This, together with investigation of the relationship between Aβ deposition and cognition, sets the stage for elucidation of the temporal sequence of the neurobiological events leading to cognitive decline. Furthermore, correlation of Aβ levels detected by PiB PET and those obtained from biopsy or postmortem specimens will allow more rigorous quantitative interpretation of PiB PET data in relation to neuropathological evaluation. Since the first human study in 2004, in vivo amyloid imaging has led to advances in our understanding of the role of Aβ deposition in human aging and cognitive decline, as well as provided new tools for patient selection and therapeutic monitoring in clinical trials.
Export Options
About this article
Cite this article as:
Sojkova J. and M. Resnick S., In Vivo Human Amyloid Imaging, Current Alzheimer Research 2011; 8 (4) . https://dx.doi.org/10.2174/156720511795745375
DOI https://dx.doi.org/10.2174/156720511795745375 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI) Patients are Characterized by Increased BDNF Serum Levels
Current Alzheimer Research Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects
Current Alzheimer Research Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research The Use of Metronidazole During Pregnancy: A Review of Evidence
Current Drug Safety Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Recent Development in Neuronal Migration Disorders: Clinical, Neuroradiologic and Genetics Aspects
Current Pediatric Reviews BDNF/NF-κB Signaling in the Neurobiology of Depression
Current Pharmaceutical Design Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Review of Pediatric Uveitis
Current Pediatric Reviews Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Case Series and Mini-Review on Elizabethkingia meningoseptica, A high Alert Organism Causing Meningitis in Premature Neonates from A Tertiary Care Hospital of Western Rajasthan
Infectious Disorders - Drug Targets Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets DLPF Targeted Repetitive Transcranial Magnetic Stimulation Improves Brain Glucose Metabolism Along with the Clinical and Electrophysiological Parameters in CBD Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets